Anteris Reports Positive Biomimetic Heart Valve Study Results
Anteris Technologies (Nasdaq:AVR) announced one-year clinical outcomes for its DurAVR transcatheter heart valve (THV) in symptomatic severe aortic stenosis patients with small aortic annuli.
- DurAVR demonstrated single-digit mean gradients and large effective orifice areas (EOAs).
- No moderate or severe paravalvular leaks and no valve-related mortality at one year.
- Low prosthesis-patient mismatch at 30 days (1.5%).
The study's findings were shared at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco, with a pooled cohort of 65 patients.
The results showed a favorable hemodynamic profile sustained to one year, plus positive clinical safety outcomes.
Author's summary: Anteris reports positive study results for DurAVR heart valve.
More News
- European Commission fines X for breaches of digital rules
- Suryakumar Yadav Breaks Past Rohit Sharma to Set New Mumbai T20 Batting Record
- Australian Cricket News Today, Dec 1: Big Bash League Sale Revolution
- Coupang Faces Major Data Breach, Affecting 33.7 Million Accounts
- India Vs South Africa 1st T20I Live Streaming: When, Where To Watch
- IPL Auction 2025
- Mitchell Starc Profile - Cricket Player Australia | Stats, ...
- The Summer I Turned On The Cricket: Why The Big Bash League Is The Place To Be
- France Activates Counter-Measures After Drone Swarm Breaches Airspace Near Nuclear Sub Base
- South Korea Calls for Tougher Penalties After Coupang Data Breach